Development of an effective therapeutic regimen for treatment of advanced pancreatic cancer using a novel immunotherapeutic agent

点击翻译按钮获取中文摘要

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumour types, with an extremely poor prognosis. It is the 7th most common cause of cancer death worldwide and the five-year survival rate remains consistently low at 3%. Without active treatment, patients with metastatic PDAC have a mean survival of 3-5 months. Even following potential curative resection, more than 80% of patients ultimately die of the disease due to local recurrence and/or distant metastasis. Current advances in surgical, adjuvant and palliative treatments have failed to improve the overall survival rate since the 1970s. Thus, new treatment strategies that are not cross-resistant with conventional chemotherapy-based regimes are imperative. A major barrier to the effective treatment of PDAC is the inaccessibility of the tumour to treatment. Furthermore, patients usually present with advanced disease that has metastasised to distant sites.Tumour-targeting oncolytic viruses (TOVs) are a new class of therapeutic that are showing immense promise in clinical trials for a number of different cancers and provide a promising platform for development of curative therapies for PDAC. TOVs not only kill the tumour cells by direct lysis but also act through multiple other mechanisms of action by targeting molecular pathways involved in carcinogenesis, as well as breaking down the immuno-suppressive tumour microenvironment and inducing a long-lasting tumour-specific immunity. Furthermore, TOVs can specifically deliver therapeutic proteins into tumours at increasing levels following viral replication within the malignant cells. Although clinical trials with various TOVs have produced evidence of response, many have ultimately disappointed, especially for PDAC. Vaccinia virus (VV) has several features that make it a promising therapeutic agent, especially since one such virus (JX594) has recently been shown to target tumours effectively after intravenous infusion, making VV an ideal TOV for treatment of inaccessible tumours such as pancreatic cancer. We have recently identified the European vaccine strain Lister vaccinia virus is an attractive platform for development of new generation of oncolytic VV for cancer treatment, especially for PDAC. Based on the lister strain, we recently developed a new generation of VV (VVTKN1L, a patent filed by QMUL Innovation Ltd), which is more tumour-specific and results in an improved antitumour efficacy. Furthermore, we have created a set of VVTKN1L vectors expressing immunomodulatory genes including VV-IL10, VV-GMCSF, VV-IL12, VV-IL15/IL15R and VV-IL-21. VVTKN1L-IL21 has demonstrated the highest therapeutic index for treatment of peritoneally disseminated pancreatic cancer. In this project we will develop an optimised therapeutic regimen by combining our novel virus with a new tumour targeted drug that regulates host immune responses as well as conventional chemotherapy (gemcitabine) for treatment of advanced pancreatic cancer.